ReviewFamilial cancer2005
SDHC mutations in hereditary paraganglioma/pheochromocytoma.
Review in Familial cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Guideline
- Gastric paraganglioma: a case report and review of literature.Frontiers in oncology · 2024Article
- Blackout in the powerhouse: clinical phenotypes associated with defects in the assembly of OXPHOS complexes and the mitoribosome.The Biochemical journal · 2020Review
- Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine.Human molecular genetics · 2020Review
- Intrinsic and Extrinsic Modulators of the Epithelial to Mesenchymal Transition: Driving the Fate of Tumor Microenvironment.Frontiers in oncology · 2020Review
- Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer.The FEBS journal · 2017Review
- Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review.Iranian journal of pathology · 2017Review
- 15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5.Endocrine-related cancer · 2015Review
- Familial pheochromocytomas and paragangliomas.Molecular and cellular endocrinology · 2014Review
- Hypertension in a teenager: a family affair.BMJ case reports · 2014Article
- Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing.Annals of surgical oncology · 2013Article
- An update on the genetics of pheochromocytoma.Journal of human hypertension · 2013Review
- New roles of carboxypeptidase E in endocrine and neural function and cancer.Endocrine reviews · 2012Review
- Novel use of F-DOPA PET/CT imaging in a child with paraganglioma/pheochromocytoma syndrome.Pediatric radiology · 2011Article
- Pathological mechanisms and parent-of-origin effects in hereditary paraganglioma/pheochromocytoma (PGL/PCC).Neurogenetics · 2011Review
- Regulation of succinate-ubiquinone reductase and fumarate reductase activities in human complex II by phosphorylation of its flavoprotein subunit.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2009Article
- Genetic analysis of high altitude paragangliomas.Endocrine pathology · 2006Review
- Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background.Cancer geneticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in genes coding for three of the four components of mitochondrial complex II can cause paragangliomas (PGLs)/pheochromocytomas. The three genes include SDHB, -C, and -D. SDHC and SDHD anchor the catalytic subunits SDHA and -B of mitochondrial complex II in the inner mitochondrial membrane. SDHD is maternally imprinted but SDHB and -C are not. While SDHD and -- to a lesser degree -- SDHB mutations have been found in many cases of hereditary PGL, SDHC mutations are rare. This article reviews the SDHC mutations described to date and discusses possible mechanisms of tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.